Abstract
Objective To assess the efficacy and safety of multimodal analgesia with different doses of nalbuphine combined with flurbiprofen on patients who received intravenous patient-controlled analgesia(PCIA) after thoracotomy. Methods Sixty patients underwent thoracotomy, ASA Ⅰ-Ⅱ, 18-65 years old, who underwent postoperative PCIA, were randomly divideded into three groups according to the digital table, nalbuphine 60 mg group(N60 group), nalbuphine 80 mg group(N80 group) and nalbuphine 100 mg group (N100 group), 20 cases in each group.All patients were given 150mg flurbiprofen, a total of 100mL.PCIA solution: the background dose was 2mL/h, PCIA dose of 0.5mL, locking time of 15min.10min before surgery, each patient was intravenously given flurbiprofen 50mg, given a loading dose of 0.1mL/kg when closed chest.All patients were followed up for 48h.The incidence of adverse reactions such as vital signs, number of times, visual analog scale(VAS) score, sedation score, nausea and vomiting were recorded. Results There were no significant differences in the age, gender, body mass index and surgery duration among the three groups(all P>0.05). The vital signs were stable within 48h after operation.The VAS scores of N60 group were higher than the other two groups(N80 group: t=7.94, 6.35, 6.49, 5.21, 5.63, all P=0.00; N100 group: t=8.41, 9.10, 5.80, 8.07, 8.18, all P=0.00) at 4, 6, 8, 24 and 48h after operation(all P 0.05). The effective/actual compression ratio of PCIA of N80 group and N100 group were significantly higher than that of N60 group (t=7.30, 8.35, all P 0.05; group N100: χ2=3.14, 0.23, 1.03, all P>0.05). Conclusion Postoperative PCIA with nalbuphine (80 mg) combined with flurbiprofen(150 mg) has significant analgesic effect and lower costs. Key words: Analgesia; Nalbuphine; Flurbiprofen; Analgesis, patient-controlled; Thoracic surgical procedures
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.